SuperworthPrestige Consumer Healthcare EPS PBH
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $3.57
- Latest quarter, Q1 FY27
- $0.61
- −36% on a year earlier
- Fiscal year 2026
- $3.91
- −9% on the year before
Prestige Consumer Healthcare's earnings per share was $3.57 over the twelve months to Jun 30, 2026, down 16% on a year earlier.
In its latest quarter, Q1 FY27, it was $0.61, down 36% on the same quarter a year before.
Over the five fiscal years to FY2026 it grew 4% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $3.91 | −9% |
| FY2025 | $4.29 | +3% |
| FY2024 | $4.17 | n/a |
| FY2023 | −$1.68 | −142% |
| FY2022 | $4.04 | +24% |
| FY2021 | $3.25 | +17% |
| FY2020 | $2.78 | n/a |
| FY2019 | −$0.71 | −111% |
| FY2018 | $6.33 | +387% |
| FY2017 | $1.30 | −31% |
| FY2016 | $1.88 | +27% |
| FY2015 | $1.48 | +6% |
| FY2014 | $1.39 | +9% |
| FY2013 | $1.28 | +73% |
| FY2012 | $0.74 | +28% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $0.61 | −36% | $3.57 | |
| Q4 FY26 | $1.13 | +13% | $3.91 | |
| Q3 FY26 | $0.97 | −20% | $3.78 | |
| Q2 FY26 | $0.86 | −21% | $4.03 | |
| Q1 FY26 | $0.95 | −3% | $4.26 | |
| Q4 FY25 | $1.00 | +2% | $4.29 | |
| Q3 FY25 | $1.22 | +15% | $4.27 | |
| Q2 FY25 | $1.09 | +2% | $4.11 | |
| Q1 FY25 | $0.98 | −8% | $4.09 | |
| Q4 FY24 | $0.98 | n/a | $4.17 | |
| Q3 FY24 | $1.06 | +2% | −$1.64 | |
| Q2 FY24 | $1.07 | +5% | −$1.66 |
Against its peers
Companies in Drug Manufacturers - General nearest Prestige Consumer Healthcare's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| Peer median | $2.38 |
Where Prestige Consumer Healthcare ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Prestige Consumer Healthcare
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.